Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bladder cancer.

Filippo de Braud1, Massimo Maffezzini, Vito Vitale

  • 1START Project, European School of Oncology, Viale Beatrice d'Este 37, 20122 Milan, Italy.

Critical Reviews in Oncology/Hematology
|February 14, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities.

Science advances·2026
Same author

Enhancing the quality and trustworthiness of large language model-generated summaries of clinical oncology literature.

JAMIA open·2026
Same author

EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.

Prostate cancer and prostatic diseases·2026
Same author

Stereotactic Body Radiation Therapy (SBRT)-Induced 68Ga-PSMA PET Bone Flare.

Clinical nuclear medicine·2026
Same author

Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Estrobolome and the Endocrine-Microbiome Axis in Breast and Endometrial Carcinogenesis.

Critical reviews in oncology/hematology·2026
Same journal

Remodeling the immune microenvironment: Engineering IL-2 variants to overcome clinical bottlenecks in PD-1 inhibitor plus chemotherapy.

Critical reviews in oncology/hematology·2026
Same journal

Neoadjuvant immunotherapy in melanoma: From pathologic response to response-adapted management.

Critical reviews in oncology/hematology·2026
Same journal

DNA polymerase epsilon catalytic subunit (POLE) in cancer: Implications for tumor biology and therapeutic strategies - A comprehensive review.

Critical reviews in oncology/hematology·2026
Same journal

Long non-coding RNAs in triple-negative breast cancer: emerging drivers of tumor biology, prognosis, and drug resistance.

Critical reviews in oncology/hematology·2026
Same journal

Alternative splicing in breast cancer drug resistance: Mechanisms, therapeutic targeting, and clinical translation.

Critical reviews in oncology/hematology·2026
See all related articles

Bladder cancer, a common urogenital tumor, has high recurrence rates. Treatment involves surgery and Bacillus Calmette-Guérin (BCG) for superficial cases, while radical cystectomy and chemotherapy are used for invasive bladder cancer.

Area of Science:

  • Uro-oncology
  • Cancer Research

Background:

  • Bladder cancer is the second most common urogenital malignancy.
  • Risk factors include tobacco smoke and aromatic amine exposure.
  • Most bladder cancers are initially superficial, but recurrence and progression are common.

Purpose of the Study:

  • To review the epidemiology, risk factors, and treatment modalities for bladder cancer.
  • To highlight the challenges in managing superficial and muscle-invasive bladder cancer.
  • To discuss the role of surgery, Bacillus Calmette-Guérin (BCG), and chemotherapy.

Main Methods:

  • Literature review of bladder cancer epidemiology and treatment outcomes.
  • Analysis of standard treatment approaches for superficial and invasive disease.
  • Evaluation of the efficacy of BCG and chemotherapy in bladder cancer management.

Related Experiment Videos

Main Results:

  • Superficial bladder cancers have high recurrence rates (50-80%) and risk of progression (10-25%).
  • Muscle-invasive bladder cancer carries a 50% risk of distant metastases.
  • BCG is effective for superficial bladder cancer prophylaxis, while radical cystectomy is standard for invasive disease.

Conclusions:

  • Effective management of bladder cancer requires tailored approaches for superficial and invasive stages.
  • BCG immunotherapy and chemotherapy show promise in improving outcomes.
  • Further research is needed to optimize treatment strategies and reduce recurrence and metastasis.